Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ALXN1850

Phase 3Biologic

ALXN1850 is one of 10 biologic programs targeting Hypophosphatasia. It is currently in Phase 3.

1

Indications

4

Total Trials

3

Active Trials

9

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypophosphatasiaActive, not recruiting

HypophosphatasiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Hypophosphatasia

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Rituxan

Folvite

Fosrenol

Velcade

SShilpa Grover, MD, MPH

Ivig

STRENSIQ

BPS804

ALXN1850

Ilofotase Alfa

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Active, not recruiting

Pediatric

NCT06079372

Phase 3Active, not recruiting

Hypophosphatasia

NCT06079281

Q3 2028

Phase 3Active, not recruiting

Treatment

NCT06079359

Clinical

Trials by Indication[1]

Hypophosphatasia2 trials

Study of ALXN1850 in Participants With Hypophosphatasia (HPP)

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04980248·15 enrolled

A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 (Recombinant Alkaline Phosphatase) Administered Subcutaneously in Adolescent (12 to < 18 Years of Age) and Adult Participants With Hypophosphatasia Who Have Not Previously Been Treated With Asfotase Alfa

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06079281·124 enrolled

Treatment1 trial

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06079359·30 enrolled

Pediatric1 trial

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06079372·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ALXN1850. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALXN1850 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALXN1850. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Related News